International Journal Of Drug Regulatory Affairs
  • Year: 2022
  • Volume: 10
  • Issue: 2

Comparison of dissolution profile for immediate-release dosage form for US and Europe

  • Author:
  • Shivam Kanojiya1, Neel Patel2, Ravish J. Patel1, Amit A. Patel1,*
  • Total Page Count: 4
  • Page Number: 35 to 38

1Ramanbhai Patel Collage of Pharmacy, Charotar University of Science and Technology, Changa388841, Gujarat, India

2Sun Pharma Advance Research Centre (SPARC), Tandalja, Vadodara, Gujarat, India390012

*Corresponding author

Online published on 15 November, 2022.

Abstract

Any oral medication product control strategy must include the creation of a dissolve method with appropriate specifications. In the creation of drug, dissolution testing is critical IV approach. In some cases, an IV dissolution test can be used instead of an in vivo dissolution test. As a result, regulatory agencies have formally acknowledged in vitro methods to determine the dissolution frequency of API from the solid oral form as a significant factor when manufacturing solid-oral-dosage forms. Dissolution tests have long been acknowledged as critical quality-control tools for ensuring batch-to-batch consistency. Following post-approval changes to pharmaceutical products, dissolution testing is also important in providing quality information of the product.

Keywords

Comparative dissolution profile (CDP), F1 and f2 factor, Office of Generic Drugs (OGD), Vitro/In-Vivo Correlations (IVIVC), European Medicines Agency (EMA), Scale up and post approval change (SUPAC), BCS Based Biowaiver, EMA, Dissolution